Učitavanje...
PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms
Poly (ADP‐ribose) polymerase (PARP) inhibitors have provided great clinical benefits to ovarian cancer patients. To date, three PARP inhibitors, namely, olaparib, rucaparib and niraparib have been approved for the treatment of ovarian cancer in the United States. Homologous recombination deficiency...
Spremljeno u:
| Izdano u: | J Cell Mol Med |
|---|---|
| Glavni autori: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley and Sons Inc.
2019
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6433712/ https://ncbi.nlm.nih.gov/pubmed/30672100 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.14133 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|